Overview

A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy

Status:
Completed

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the safety and efficacy of CCX354-C in subjects with rheumatoid arthritis partially responsive to methotrexate therapy.

Phase:

Phase 2

Details

Lead Sponsor:

ChemoCentryx

Treatments:

Methotrexate